ZFGN Profile
Zafgen, Inc. (ZFGN) was a biopharmaceutical company based in Boston, Massachusetts that focused on developing therapies for patients suffering from metabolic diseases, including obesity and type 2 diabetes.
The company's lead product candidate, Beloranib, was a first-in-class injectable drug that selectively targeted and modulated the activity of the MetAP2 enzyme, which plays a key role in regulating metabolism. Beloranib was designed to help patients with severe obesity who had failed to achieve meaningful weight loss through diet and exercise alone.
However, in 2016, Zafgen announced that it was discontinuing development of Beloranib after the drug was associated with a higher incidence of thrombotic events (blood clots) in clinical trials. The company subsequently shifted its focus to developing other MetAP2 inhibitors with improved safety profiles, but in 2019, Zafgen announced that it was winding down its operations and liquidating its assets due to a lack of funding.
As of February 2023, Zafgen is no longer a publicly traded company and has ceased all business operations.
|
